Value Sense
EW
Edwards Lifesciences Corporation (EW)
Last Price$71.4(0.3%)
Market Cap$43.4B
Intrinsic value score
6/10
Good
Intrinsic value
$54.1
DCF value - $43.3 Relative value - $64.9
Overvalued
24.2%
LTM P/E
10.4x
Peer set median 39.4x
Discount rate
9.2%
EW
is 24.2% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

EW Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 EW Relative Value is $66.1, which is overvalued by 7.5%, compared to current share price of $71.4.
DCF Value vs Current Share Price
As of Mar 03, 2025 EW DCF Value is $43.6, which is overvalued by 38.9%, compared to current share price of $71.4.
Methodology
Price per share, $
EW
Intrinsic value$54.1
Overvalued by24.2%
Current share price
71.4
Relative value
66.1
DCF value
43.6

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

EW Historical Intrinsic Value

Crunching data... Almost there!

EW vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Edwards Lifesciences Corporation logo
Edwards Lifesciences CorporationEW
(24.2%)
(9.4%)
202.2%
76.7%
Median Peer Set
5.6%
72.0%
11.8%
Boston Scientific Corporation logo
Boston Scientific CorporationBSX
(67.4%)
17.6%
16.7%
11.1%
Insulet Corporation logo
Insulet CorporationPODD
(50.7%)
30.0%
4,364.6%
12.2%
DexCom, Inc. logo
DexCom, Inc.DXCM
(49.8%)
11.3%
(1.4%)
14.3%
Stryker Corporation logo
Stryker CorporationSYK
(22.7%)
10.2%
(5.8%)
13.2%
STERIS plc logo
STERIS plcSTE
(10.4%)
3.6%
257.9%
7.4%
Align Technology, Inc. logo
Align Technology, Inc.ALGN
8.5%
3.4%
26.0%
11.5%
Medtronic plc logo
Medtronic plcMDT
21.5%
3.6%
(2.1%)
11.4%
Abbott Laboratories logo
Abbott LaboratoriesABT
24.5%
4.6%
134.5%
31.9%
Zimmer Biomet Holdings, Inc. logo
Zimmer Biomet Holdings, Inc.ZBH
72.0%
6.5%
253.2%
13.8%
Koninklijke Philips N.V. logo
Koninklijke Philips N.V.PHG
146.8%
(0.8%)
118.1%
(3.9%)

Explore more intrinsic value tools hub for EW

DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate

FAQ

What is Edwards Lifesciences Corporation intrinsic value?

As of Mar 03, 2025, Edwards Lifesciences Corporation Intrinsic Value is $54.1. This suggests it may be overvalued by 24.2% compared to its current price of around $71.4.

What is Edwards Lifesciences Corporation DCF (discounted cash flow) valuation?

As of Mar 03, 2025, Edwards Lifesciences Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $43.6. This suggests it may be overvalued by 38.9% to its current price of around $71.4, using a discount rate of 9.2% and terminal growth rate of 3.0%.

Is Edwards Lifesciences Corporation overvalued or undervalued?

Edwards Lifesciences Corporation is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $54.1, compared to a market price of around $71.4. This suggests a potential overvaluation of 24.2%.